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Abstract
Background Opioid-induced constipation (OIC) has
negative effects on quality of life (QOL). Prucalopride is a
new, selective 5-HT4 agonist and enterokinetic with strong
clinical data in chronic constipation. This study investi-
gated the efﬁcacy, safety, and tolerability of prucalopride
in patients with noncancer pain and OIC.
Methods A phase II, double-blind, placebo-controlled
study of 196 patients randomized to placebo (n = 66),
prucalopride 2 mg (n = 66) or 4 mg (n = 64), for
4 weeks, was carried out. The primary endpoint was the
proportion of patients with increase from baseline of C1
spontaneous complete bowel movement (SCBM)/week.
Secondary endpoints [proportion of patients with C3
SCBM/week, weekly frequency of (SC)BM, severity of
constipation, and efﬁcacy of treatment], adverse events
(AEs), and safety parameters were also monitored.
Results More patients had an increase from baseline
of C1 SCBM per week (weeks 1–4) in the prucalopride
groups [35.9% (2 mg) and 40.3% (4 mg)] versus placebo
(23.4%), reaching statistical signiﬁcance in week 1. Over
weeks 1–4, more patients in the prucalopride groups
achieved an average of C3 SBM per week versus placebo
(60.7% and 69.0% versus 43.3%), reaching signiﬁcance
at week 1. Prucalopride 4 mg signiﬁcantly improved
patient-rated severity of constipation and effectiveness of
treatment versus placebo. Patient Assessment of Consti-
pation-Symptom (PAC-SYM) total scores and Patient
Assessment of Constipation-Quality of Life (PAC-QOL)
total and satisfaction subscale scores were improved. The
most common AEs were abdominal pain and nausea.
There were no clinically relevant differences between
groups in vital signs, laboratory measures or electrocar-
diogram parameters.
Conclusion In this population with OIC, prucalopride
improved bowel function and was safe and well tolerated.
Keywords Opioid-induced bowel dysfunction 
Prucalopride  Safety  Efﬁcacy  Constipation
Introduction
It has been estimated that globally around 365 million
prescriptions were written for opioids in 2005 [1, 2]. In
addition to their intended therapeutic (analgesic) effect,
opioids often lead to opioid-induced bowel dysfunction
(OBD), which can have a signiﬁcant adverse effect on
patients’ quality of life (QOL) that persists for as long as
opioid therapy is administered [3, 4]. By activating
opioid receptors in the gastrointestinal (GI) tract, opioids
inhibit the normal release of excitatory and inhibitory
neurotransmitters, thereby interrupting the rhythmic con-
tractions required for normal intestinal motility and
reducing mucosal secretions [5, 6]. Normal bowel func-
tion is inhibited [7], and constipation is therefore a
common side-effect of opioid treatment, along with
These results have been presented in part at Digestive Disease Week
2008 and were published as an abstract: Moulin et al.
Gastroenterology 2008; 134:A92.
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bloating, delayed GI transit, and the formation of hard,
dry stools. This can cause straining, painful defecation,
incomplete evacuation, and a sensation of bowel
obstruction [7–10].
Estimates of the frequency of constipation range from
15% to 90% in patients receiving opioids for noncancer
pain [9, 11, 12]. Patients rarely develop tolerance to the
constipation-related effects of opioids, and effects tend to
increase with increasing doses of opioid [13]. Some
patients receiving long-term opioid treatment for pain
would rather endure their pain than the constipation that
opioids may cause [4].
To promote bowel movements in patients with OBD,
laxatives are most commonly used. However, they do not
target the underlying cause and results are therefore
unpredictable, and their clinical efﬁcacy can be difﬁcult to
assess due to the lack of high-quality placebo-controlled
trials. Stool softeners, stimulant laxatives, osmotic agents,
and lubricants are all prescribed but are not effective in all
patients [3, 4].
Prucalopride is the ﬁrst compound of a new class of
highly selective 5-HT4 agonists with strong enterokinetic
activity [14–16]. A comprehensive phase III dataset sup-
ports its efﬁcacy in chronic constipation patients for whom
laxatives do not provide adequate relief.
In preclinical studies it has been shown that prucalo-
pride can induce giant migrating contractions (GMCs),
stimulate proximal colonic motility, enhance gastro-pyl-
oro-duodenal motility, and accelerate delayed gastric
emptying [17]. Phase II studies in patients with chronic
constipation have demonstrated that oral prucalopride
treatment at a dose of 0.5–4 mg increases stool fre-
quency and decreases stool consistency [14, 18–21].
Phase III studies have shown that prucalopride can nor-
malize bowel habit [as deﬁned by a mean of C3 spon-
taneous complete bowel movements (SCBM) per week]
in *30% of patients (2 mg dose, versus 12% with pla-
cebo, P\0.001) and increase the proportion of patients
with an increase of C1 SCBM per week (47% with 2 mg
versus 26% with placebo, P\0.001) [22–24]. Prucalo-
pride treatment also results in improvements in other
associated symptoms and QOL [22–24]. Prucalopride has
been well tolerated in all patient groups studied to date
during treatment and in long-term follow-up [22–26].
Prucalopride has recently been approved by the EMA for
symptomatic treatment of chronic constipation (CC) in
women for whom laxatives provide inadequate relief.
The objective of this phase II study is to evaluate the
efﬁcacy, the effects on QOL, and the safety and tolera-
bility of prucalopride in patients with noncancer pain
suffering from OIC.
Methods
Design
This was a multicenter, phase II, randomized, double-
blind, placebo-controlled study conducted in eight coun-
tries and involving 60 study centers ranging from hospitals
to research clinics where patients were being treated for
noncancer pain. Treatment duration was 4 weeks. The trial
was designed by Janssen Research Foundation and ran
from March 1999 to 2000. The study was conducted in
accordance with the principles of the Declaration of Hel-
sinki and the principles of good clinical practice (GCP),
and all participants gave written informed consent before
they were admitted to the trial. The ﬁnal study protocol and
amendments were approved by independent Ethics Com-
mittees or the appropriately constituted Institutional
Review Boards (IRBs).
The clinical development program for prucalopride was
stopped in 2003 by Janssen Research foundation after an
internal strategic prioritization exercise, and was trans-
ferred to Movetis N.V. in 2007 as part of a portfolio of GI
compounds that is now being further developed. At this
time, the data from this randomized, controlled trial
investigating the effect of prucalopride on OIC were
reviewed. It was decided that these data were of general
interest and should be offered for publication.
Inclusion and Exclusion Criteria
Male and female (non-pregnant and non-breastfeeding)
outpatients of at least 18 years of age were eligible to enter
the 2-week run-in period (3 weeks if the patient was using
agents that inﬂuenced bowel habit) if they had OIC clearly
secondary to chronic daily opioid use, starting at least
2 weeks prior to the ﬁrst visit and expected to last for at
least 6 further weeks, expected to stay on a minimum daily
dose of the same opioid for at least 6 weeks, and with no
history of chronic constipation prior to commencement of
opioid therapy. Patients were recruited with chronic pain of
any etiology (except cancer) that required daily mainte-
nance treatment with opioids. Patients taking laxatives were
required to stop their use during run-in and switch to the
rescue medication [Dulcolax
 (bisacodyl) and/or enemas].
Patients were eligible for randomization if, during the
run-in period, patient-completed diary of bowel move-
ments recorded a weekly average of two or fewer sponta-
neous bowel movements that resulted in a feeling of
complete evacuation (SCBM), if they answered positively
on the question ‘‘if they were bordered by their constipa-
tion?’’ and if they had stopped laxative treatment and
switched to bisacodyl and enemas. A spontaneous bowel
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within a period of 24 h by the intake of a laxative agent.
Patients were excluded if their constipation was thought to
be caused by factors other than opioid therapy, such as
other drugs, endocrine, metabolic, neurological, or other
serious illnesses.
Treatments
Patients were allocated to one of three groups (according to
a randomization code) to take placebo, prucalopride 2 mg,
or prucalopride 4 mg orally once daily (before breakfast)
for 4 weeks. Balancing ensured that equal numbers of
patients entered each treatment group. Patients and inves-
tigators were blinded to treatment received.
Patients had to remain on a stable minimal daily main-
tenance dose of opioid for the duration of the trial, and a
change in the dose or combination with another opioid was
only allowed for management of breakthrough pain.
Combination of the opioid with a nonnarcotic analgesic
was allowed.
Agents that might inﬂuence bowel habit, such as anti-
cholinergics, spasmolytics, and prokinetics, were discon-
tinued 21 days before the start of the study and throughout
the treatment period. Antidepressant treatment was allowed
if the patient had been taking a stable dose of antidepres-
sant for at least 4 weeks prior to inclusion in the trial.
During the study, laxatives were not allowed, apart from
a single dose of 10 mg bisacodyl which was allowed as
rescue medication if the patient had not had a bowel
movement for 48 h. A further increase in the dose was
allowed if a single dose was insufﬁcient, and after this an
enema could be administered. No bisacodyl or enema was
allowed within 24 h of (before or after) the ﬁrst intake of
trial medication.
Assessments
Efﬁcacy Assessments
Diary data and questionnaires were collected during the
run-in and the treatment periods. Bowel movement data
(time, consistency, sensation of complete evacuation,
straining) were recorded in the diary. Run-in data provided
baseline values for treatment comparisons. A SBM is a BM
not preceded within a period of 24 h by the intake of a
laxative agent. A SCBM is a SBM that resulted in a feeling
of complete evacuation.
The primary endpoint was the proportion of patients
with an average increase from baseline of C1 SCBM per
week during the 4-week study period. Secondary endpoints
included the proportion of patients having, on average, C3
SCBM per week during the 4-week trial period and the
average weekly frequency of SCBMs, SBMs, and all BMs.
All SCBM and BM parameters were assessed at each
individual week and over the total 4-week duration, based
on diary data recorded by patients.
Patients’ global assessment of severity of constipation
and efﬁcacy of treatment were determined as follows. For
severity of constipation, each patient was asked to record
his/her severity of constipation over the past 2 weeks, on
the following ﬁve-point scale: absent (0), mild (1), mod-
erate (2), severe (3), very severe (4). This questionnaire
was completed at baseline, week 2, and week 4 or at
endpoint. For assessment of treatment efﬁcacy, each
patient was asked to rate his/her efﬁcacy of treatment using
the following ﬁve-point scale: not at all effective (0), a
little bit effective (1), moderately effective (2), quite a bit
effective (3), extremely effective (4). This questionnaire
was completed at week 2 and at week 4.
The Patient Assessment of Constipation-Symptom
(PAC-SYM) and the Patient Assessment of Constipation-
Quality of Life (PAC-QOL) questionnaires were also used.
Higher scores reﬂect greater severity of symptoms and
poorer QOL, respectively.
The PAC-SYM was completed at baseline, week 2, and
week 4, based on how patients felt in the previous 2 weeks,
and PAC-QOL was completed at baseline and at week 4.
The PAC-SYM is a validated questionnaire that is used to
assess the severity of 12 constipation-related symptoms
grouped into three subscales: stool symptoms, abdominal
symptoms, and rectal symptoms [27]; it has also been
validated for use in opioid-induced constipation [28].
Patients rated the severity of each symptom on a ﬁve-point
scale from 0 (absent) to 4 (very severe), and scores are
reported as an average total score or subscale score. The
PAC-QOL is a validated questionnaire which assesses 28
items grouped into four subscales: physical discomfort,
psychosocial discomfort, worries and concerns, and satis-
faction [29]. As with the PAC-SYM questionnaire, items
are rated on a ﬁve-point scale from 0 to 4, and scores are
reported as an average total score or subscale score.
Safety Assessments
Adverse events (AEs) were reported from the ﬁrst visit to
the end of the trial. At the ﬁrst visit, a medical and surgical
history was taken; physical examination, laboratory eval-
uation, and ECGs were performed at ﬁrst and last visit (or
discontinuation); and vital signs were recorded at each
visit.
Twelve-lead ECGs were taken at the start of the study
and after 4 weeks of treatment. ECGs were analyzed cen-
trally, and the intervals RR, PR, QRS, and QT were mea-
sured manually with electronic calipers. QT interval was
corrected for heart rate according to Bazett (QTcB) and
2914 Dig Dis Sci (2010) 55:2912–2921
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interpretations were validated by a cardiologist experi-
enced in reading ECGs.
Statistical Analysis and Sample Size
The sample size estimation was based on assumed
response rates for the primary endpoint (25% for placebo
and 55% for prucalopride doses), 80% power, and sig-
niﬁcance level of 2.5% (corrected for two comparisons).
This resulted in a sample size of 48 patients per group,
which was then corrected to account for 20% of patients
with expected insufﬁcient diary data. Therefore, the
required sample size was 60 patients per group (180
patients in total).
All statistical tests were interpreted at the 5% signiﬁ-
cance level (two-sided).
Intent-to-treat analysis and two-way analysis of variance
(ANOVA) was used for continuous variables including
factors for treatment, baseline, and country. The van Elt-
eren test was used to control for country for between-
treatment-group comparisons of ordinal categorical vari-
ables, and the Cochran–Mantel–Haenszel test for nominal
categorical variables.
Holm’s step-down procedure was used for interpretation
of multiple pairwise comparisons of ordinal variables, and
Dunnett’s test was used on least-square means for contin-
uous variables.
Results
One hundred ninety-six patients under the care of 54
investigators were randomized: 66 to placebo, 66 to pru-
calopride 2 mg, and 64 to prucalopride 4 mg. This group
formed the safety set. The population, the primary popu-
lation for efﬁcacy and QOL analyses, comprised 190
patients. The six patients (all from the same study center)
not included in the population were excluded for reasons
related to good clinical practice. A total of 29 patients
withdrew before study completion (Fig. 1).
The median age of patients was 50 years (range 21–86
years), and 61.2% of the patients were female. There were
no statistically signiﬁcant differences between the groups
in terms of age, race or weight (Table 1).
Table 1 also summarizes the opioid therapy taken by
patients during the trial; the majority of patients were taking
morphine (67.9%), and two or more opioids were used by a
number of patients for control of breakthrough pain. Opioids
for maintenance pain were taken for an average of 6.7–6.9
days per week during the run-in as well as during weeks 1–4,
with no signiﬁcant difference between treatment groups.
Patients had an average of 0.3–0.5 SCBM/week and
1.5–2.4 SBM/week at baseline (Table 2). The most fre-
quent patient complaints related to constipation were dif-
ﬁculty in defecation (36–45%), straining (33–39%), and
hard stools (27–39%). Patients could indicate more than
one complaint.
Fig. 1 Disposition of patients
throughout the study
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The percentage of patients with an increase from baseline
of C1 SCBM per week averaged over 4 weeks was higher
in the prucalopride groups compared with placebo, reach-
ing statistical signiﬁcance in the ﬁrst week of treatment for
both 2 and 4 mg prucalopride versus placebo (P = 0.021
and 0.002, respectively; Fig. 2).
Averaged over weeks 1–4, more patients in the prucal-
opride 2 and 4 mg groups had C3 SCBM per week com-
pared with the placebo group (23.4% and 12.9% versus
9.4%), reaching signiﬁcance at week 1 (25% and 23.3%
versus 3.1%, P B 0.001).
Over 4 weeks of treatment, more patients in the pru-
calopride 2 and 4 mg groups had on average C3 SBM per
week compared with the placebo group (60.7% and 69.0%
versus 43.3%, respectively), which was signiﬁcant for the
4 mg prucalopride group (P = 0.01). After 1 week of
treatment, 67.2% of the 2 mg and 81.7% of the 4 mg
prucalopride group were responders for this parameter
compared with 46.9% of placebo-treated patients
(P = 0.034 and P\0.001 for 2 and 4 mg prucalopride
versus placebo, respectively). Note that at run-in, 29.7%,
32.3%, and 19.0% of patients already had C3 SBM per
week in the 2 mg prucalopride, 4 mg prucalopride, and
placebo group, respectively.
Average weekly frequencies of SCBM and SBM were
signiﬁcantly higher in the prucalopride treatment groups
compared with placebo (Table 2), in the 4 mg prucalopride
group in week 1 for both frequencies, and additionally over
the 4-week treatment for the SBM frequency.
The proportion of patients with an increase of C1 SBM
per week, or C1 BM per week were all higher in the
prucalopride treatment groups than in the placebo group,
with statistically signiﬁcant differences after the ﬁrst week
of treatment for the 4 mg prucalopride group (Table 2).
When compared with placebo, the mean decrease in the
patient-assessed severity of constipation (rated on the ﬁve-
point scale from ‘‘absent = 0’’ to ‘‘very severe = 4’’) was
signiﬁcantly greater for the prucalopride 4 mg group
Table 1 Characteristics of study population and opioid therapy taken
during the trial
Placebo
(n = 66)
Prucalopride
2m g( n = 66)
Prucalopride
4m g( n = 64)
Characteristic
Median (range)
age, years
49 (24–80) 51 (29–86) 50.5 (21–81)
Caucasian, n (%) 66 (100) 65 (98.5) 63 (98.4)
Median (range)
weight, kg
70 (44–117) 73.5 (45–117) 75 (42–103)
Opioids taken, n (%)
Codeine 9 (13.6) 11 (16.7) 4 (6.3)
Dihydrocodeine 1 (1.5) 0 (0.0) 1 (1.6)
Fentanyl 11 (16.7) 12 (18.2) 5 (7.8)
Hydromorphone 0 (0.0) 3 (4.5) 7 (10.9)
Morphine 48 (72.7) 45 (68.2) 40 (62.5)
Other 6 (9.1) 10 (15.2) 14 (21.9)
Oxycodone 8 (12.1) 4 (6.1) 4 (6.3)
Table 2 Frequency and changes in frequency of bowel movements
Variable Placebo Prucalopride 2 mg Prucalopride 4 mg
Mean (SE) average weekly frequency of SCBM
a
Baseline 0.3 (0.07) 0.5 (0.11) 0.3 (0.08)
Week 1 0.6 (0.14) 1.6 (0.28) 1.8 (0.35)**
Weeks 1–4 0.9 (0.17) 1.6 (0.25) 1.4 (0.23)
Mean (SE) average weekly frequency of SBM
b
Baseline 1.5 (0.23) 2.3 (0.23) 2.4 (0.36)
Week 1 2.9 (0.34) 4.5 (0.40) 6.0 (0.62)***
Weeks 1–4 3.0 (0.34) 4.5 (0.42) 4.9 (0.60)*
Proportion of patients with an average increase of C1 BM per week, n
(%)
c
Week 1 22 (34.4) 28 (43.8) 37 (61.7)**
Weeks 1–4 15 (25.0) 22 (36.1) 24 (41.4)
Proportion of patients with an average increase of C1 SBM per week,
n (%)
d
Week 1 28 (43.8) 37 (57.8) 45 (75.0)***
Weeks 1–4 29 (48.3) 33 (54.1) 37 (63.8)
a,b * P B 0.05, ** P B 0.01, *** P B 0.001, pairwise comparison of
change from baseline versus placebo
c,d ** P B 0.01, *** P\0.001, pairwise comparison versus placebo
Fig. 2 Effect of prucalopride on the primary efﬁcacy endpoint.
Proportion of patients with an increase of C1 SCBM per week from
baseline, at week 1 and averaged over weeks 1–4, in patients treated
with prucalopride (2 and 4 mg) and placebo. *P\0.021 and
P = 0.002, respectively, versus placebo
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point (P = 0.029; Table 3).
The proportion of patients in the prucalopride groups
rating their treatment as extremely effective or quite a bit
effective was higher than placebo at each timepoint.
Overall the efﬁcacy of treatment was rated signiﬁcantly
higher compared with placebo for prucalopride 4 mg at
week 2 (P\0.001) and week 4 (P = 0.005; Table 3).
Prucalopride treatment increased the percentage of stools
with normal consistency and decreased the percentage of
hardness of stools (data not shown).
Symptoms of constipation, as rated by the PAC-SYM
questionnaire, improved more in treated patients compared
with placebo (NS). Compared with placebo, almost as
many patients in the 2 mg group as in the 4 mg group
improved by C1 point from baseline on the PAC-SYM
total score (Fig. 3; 22.8% and 25.0%, respectively, versus
12.5%). Stool and rectal symptoms tended to improve the
most with prucalopride.
The mean change from baseline in the PAC-QOL total
score and the satisfaction subscale score at week 4 was
greater in treated patients compared with placebo; how-
ever, this did not reach statistical signiﬁcance. A nonsig-
niﬁcant but dose-related trend was also seen in the
proportion of patients improving by C1 point on the PAC-
QOL satisfaction subscale (Fig. 3).
Regarding laxative use, there was a decrease in the mean
number of laxative tablets (Dulcolax
, bisacodyl) in all
groups, including prucalopride. This decrease was signiﬁ-
cantly greater in both prucalopride groups compared with
placebo [P = 0.035 (prucalopride 2 mg); P = 0.005
(prucalopride 4 mg)] at week 1 (Table 4).
Safety
All 196 randomized patients who took at least one dose of
double-blind medication were included in the safety
analysis.
Adverse Events
The incidence of treatment-emergent AEs was 48.5% with
placebo (32/66), 57.6% with prucalopride 2 mg (38/66),
and 50.0% with prucalopride 4 mg (32/64).
The most frequently reported AEs were related to the GI
system: abdominal pain and nausea. Abdominal pain was
more frequently reported in the prucalopride 4 mg group
(16/64, 25.0%) compared with the prucalopride 2 mg
group (8/66, 12.1%) and placebo (6/66, 9.1%). In the body
as a whole, pain was the most frequently reported AE
Table 3 Patient-assessed severity of constipation and treatment
efﬁcacy
Variable Placebo Prucalopride
2m g
Prucalopride
4m g
Patient-assessed severity of constipation (ﬁve-point rating scale from
‘‘absent = 0’’ to ‘‘very severe = 4’’)
Baseline
Rating 2.75 2.59 2.71
Week 2
Rating 2.6 2.31 2.02
Mean change from baseline -0.12 -0.32 -0.68**
Endpoint
a
Rating 2.45 2.22 1.98
Mean change from baseline -0.27 -0.38 -0.71*
Patient-assessed efﬁcacy of treatment, n (%)
Week 2
Not at all or a little bit
effective
39
(67.3)
35 (56.5) 25 (40.4)
Moderately effective 11
(19.0)
13 (21) 12 (21)
Quite or extremely
effective
8 (13.7) 14 (22.5)
 22 (38.6)

Endpoint
a
Not at all or little bit
effective
37
(61.7)
31 (49.2) 24 (41.4)
Moderately effective 13
(21.7)
17 (27) 12 (20.7)
Quite or extremely
effective
10
(16.6)
15 (23.8) 22 (37.9)

*P B 0.05, ** P B 0.01, pairwise comparison of change from base-
line versus placebo (Dunnett’s procedure)
 P B 0.05,
 P B 0.01,
 P B 0.001, comparison of overall efﬁ-
cacy versus placebo
a Endpoint = week 4 data, or previous recorded timepoint if week 4
not available
Fig. 3 Percentage of patients achieving improvement of C1 point on
the PAC-SYM questionnaire and PAC-QOL satisfaction subscale
after 4 weeks of treatment. Proportion of patients with an improve-
ment of C1 point (out of 4) in PAC-SYM total score and PAC-QOL
satisfaction subscale score at week 4 (or endpoint)
Dig Dis Sci (2010) 55:2912–2921 2917
123[prucalopride 2 mg, 4/66 (6.1%); prucalopride 4 mg, 2/64
(3.1%); placebo 3/66 (4.5%)]. Headache [prucalopride 2
mg, 4/66 (6.1%); prucalopride 4 mg, 5/64 (7.8%); placebo
3/66 (4.5%)] was the most common nervous system dis-
order (Fig. 4).
During the treatment phase, 38 patients reported severe
AEs (13 on placebo, 11 on prucalopride 2 mg, 14 on pru-
calopride 4 mg). Of these, 25 patients had possibly drug-
related AEs (7 on placebo, 9 on prucalopride 2 mg, 9 on
prucalopride 4 mg). The incidence of severe abdominal
pain and headache was slightly higher in the prucalopride
4 mg group than placebo, but there were no relevant dif-
ferences between the groups for severity of other AEs and
there was no clear dose relationship. Overall, the majority
of AEs were considered as not likely to be related to the
trial medication by the investigator. The AEs that were
considered probably or very likely related to trial medi-
cation were mostly of GI origin.
A total of ten patients had serious AEs (four in each of
the placebo and prucalopride 2 mg groups, none in the
prucalopride 4 mg group during treatment; one in the
placebo group during run-in and one in the prucalopride
4 mg group after treatment). No deaths were reported.
There were 15 patients with treatment-emergent AEs
leading to discontinuation of treatment: 7 with placebo, 3
with prucalopride 2 mg, and 5 with prucalopride 4 mg.
Abdominal pain was the most common reason for dis-
continuation in all treatment groups; other reasons for
discontinuation were diverse and mostly unrelated to trial
medication.
Vital Signs, Laboratory, ECG Parameters
No clinically relevant or consistent differences between
treatment groups were observed for vital signs, laboratory
or ECG parameters including heart rate, PR and QT
intervals, QRS width, and corrected QT intervals (QTcB
and QTcF; data not shown).
Discussion
Constipation is a common problem in patients regularly
taking opioids for the treatment of chronic pain [3]. While
laxatives are commonly recommended and prescribed to
prevent OIC, no randomized controlled trials of laxatives
for OIC have been reported. Laxatives may be effective in
many patients with OIC, but they may not be effective or
suitable in all patients. A recent survey in the USA among
patients with constipation (including opioid-induced con-
stipation) demonstrated that 47% of patients using laxa-
tives were not completely satisﬁed with their treatment,
mainly for reasons of efﬁcacy [30]. Osmotic laxatives can
be unpalatable [31], while bulk-forming laxatives require
large water intakes and are therefore not ideal in elderly or
immobile people.
Opiate antagonists are being investigated for the treat-
ment of OIC and postoperative ileus. Currently in the UK
and Europe, Relistor
 (methylnaltrexone bromide) has
been approved for the treatment of OIC in patients with
advanced illness. Methylnaltrexone bromide, which is
administered by injection only, improves the 4-h laxation
response versus placebo, and is generally well tolerated,
although serious AEs have been reported [32]. Addition of
oral naloxone to oxycodone has also been shown to
improve bowel function with no reduction in analgesic
efﬁcacy [33, 34], and use of alvimopan, a peripherally
acting opioid antagonist, is also promising in early-phase
studies in OIC [35], although this agent currently only has
Table 4 Average Dulcolax
 (bisacodyl) tablets per week
Timepoint Placebo Prucalopride 2 mg Prucalopride 4 mg
n Mean Mean change n Mean Mean change n Mean Mean change
Baseline 63 4.6 – 64 4.2 – 62 4.1 –
Week 1 64 3.2 -1.3 64 1.9 -2.3* 60 1.6 -2.5**
Weeks 1–4 60 2.9 -1.4 61 1.9 -2.4 58 2.2 -2.2
* P B 0.05; ** P B 0.01 versus placebo
Fig. 4 Treatment-emergent adverse events reported by C5% of
patients in any group
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123limited approval for short-term hospital use in postopera-
tive ileus.
Prucalopride is the ﬁrst selective serotonin 5-HT4
receptor agonist that has been shown to be effective in
patients with chronic constipation [14, 18, 19, 21, 23, 36–38].
In this phase II study of patients with OIC, prucalopride
was effective during the ﬁrst week of treatment with a
relatively stable effect thereafter. Over the 4 weeks of
treatment, 40% of patients taking 4 mg prucalopride
achieved the primary efﬁcacy endpoint of an increase
of C1 SCBM from baseline, and half of patients taking
4 mg achieved this endpoint at week 1 (P B 0.05 versus
placebo). There was a corresponding signiﬁcantly greater
decrease in laxative use in the prucalopride groups than in
the placebo group.
In the present study, prucalopride-treated patients had
also improvements in a range of additional outcomes,
including symptoms and QOL. Constipation is not just
related to frequency of BM, but also to symptoms, which
together impact patients’ functioning and well-being, and
result in dissatisfaction with bowel function and ineffective
treatments. More than 70% of constipated patients refer to
the discomfort of hard stools, straining, bloating, abdomi-
nal discomfort, and feelings of incomplete evacuation as
being severe [30]. It has been suggested therefore that
treatment of constipation should have an impact on ‘‘at
least several’’ of the attributes that are rated as most
important by patients, including relief of constipation
symptoms such as straining, hard or lumpy stools, infre-
quent stools, and improved quality of bowel movements
[30]. There is little consistent evidence from double-blind,
randomized controlled trials that traditional laxatives treat
symptoms other than frequency of bowel movements in the
long term [30, 39]. In the present study, patients taking
prucalopride reported a larger improvement than did
patients taking placebo in the severity of their constipation
and the efﬁcacy of treatment, as measured by the patient-
reported PAC-SYM and PAC-QOL questionnaires.
The effect size on bowel movements observed was
comparable to those in larger trials of prucalopride in
chronic constipation (non-opioid-induced). Of patients in
the 2 and 4 mg prucalopride groups, 36% and 40% (versus
23.4% of patients in the placebo group) had an improve-
ment of C1 SCBM per week, over the 4 weeks of treat-
ment. This compares well with the prucalopride phase III
studies, where 38–47% of patients improved by C1 SCBM
from baseline with 2 mg prucalopride versus 21–28% with
placebo [22–24]. Results with 4 mg prucalopride in these
phase III studies were similar to those with the 2 mg dose.
Although, in the current study, statistical signiﬁcance was
not reached for the primary and key secondary endpoints
over the whole treatment period, this is most likely due to
the smaller sample size in this study based on a power
calculation estimating a 30% difference. However, a con-
sistent trend was observed in prucalopride’s effect on
bowel movements, symptoms, and quality of life.
Consistent with the three phase III trials of prucalopride
in chronic constipation, there was little difference in the
frequency of AEs between placebo and prucalopride
groups. The most frequent AEs reported in chronic con-
stipation patients on prucalopride treatment were abdomi-
nal pain, nausea, diarrhea (related to the pharmacodynamic
effect of the compound), and also headache. The incidence
of these AEs in the OIC population of this trial was similar
across all groups, except for abdominal pain, which was
more commonly reported in the 4 mg prucalopride group
than the 2 mg prucalopride and placebo groups, possibly
related to the pharmacodynamic effect of prucalopride.
There was no difference between treatment groups in
severity of AEs, except for a slightly higher incidence of
severe abdominal pain in the 4 mg prucalopride group
versus placebo. There were no deaths during this trial, and
serious AEs were considered to be doubtfully or not related
to prucalopride treatment.
There were no clinically relevant differences in labora-
tory abnormalities between the groups, and there were no
signiﬁcant changes in vital signs from baseline in the
prucalopride groups. There were also no cases of serious
cardiac events with prucalopride. As prucalopride is not
metabolized via CYP 3A4, no interactions with other
medications are expected.
In general, the 2 mg dose of prucalopride is effective in
this population, but as there was little increase in AEs with
the 4 mg dose, it may be appropriate to increase to the
4 mg dose in patients with more severe complaints or in
whom the 2 mg dose is well tolerated but not effective.
In this population with OIC, more patients in the 2 and
4 mg prucalopride groups had an increase of C1 SCBM per
weekfrombaselinecomparedwithplacebooverweeks 1–4,
reaching signiﬁcance at week 1. Over the 4 weeks of treat-
ment, improvements were seen in other efﬁcacy parameters
with 2 and 4 mg prucalopride versus placebo, although not
always reaching statistical signiﬁcance.
The results in this smaller group were in line with those
seen in larger pivotal studies of prucalopride in chronic
constipation and suggest improved bowel movement fre-
quency, reduction of symptoms, and improvement of
patients’ quality of life and satisfaction.
In addition, prucalopride was safe and well tolerated in
this population with OIC.
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